SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 10, 1996
CELLEGY PHARMACEUTICALS, INC.
- --------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware
----------------------------------------------
(State or other jurisdiction of incorporation)
0-26372 82-0429727
------------ ---------------
(Commission (IRS Employer
File Number) Identification
Number)
1065 East Hillsdale Blvd., Suite 418, Foster City, CA 94404
---------------------------------------------------------------
(Address of principal executive offices, including zip code)
Registrant's telephone number, including area code: (415) 524-1600
---------------
This report on Form 8-K consists of 5 sequentially numbered pages.
<PAGE>
ITEM 5: OTHER EVENTS.
LOSS OF NAMED EXECUTIVE OFFICERS
On July 10, 1996 Cellegy Pharmaceuticals, Inc. (the "Company")
announced the deaths of William E. Bliss, its President and Chief Executive
Officer, and Lionel N. Simon, Ph.D., its Vice President, Corporate Development,
in an automobile accident. Dr. Carl Thornfeldt, the Company's Chairman of the
Board, has been named Acting Chief Executive Officer. Dr. Thornfeldt, Dr. Denis
Burger, a Director, Dr. Michael Francoeur, Vice President of Research and
Development, and A. Richard Juelis, Vice President, Finance and Chief Financial
Officer, will serve on a transition committee responsible for continuing the
Company's corporate development and operations. The Company has also established
a search committee, headed by Dr. Burger, and engaged Heidrick & Struggles, the
executive recruiting firm which originally recruited Mr. Bliss, to conduct a
nationwide search for a new Chief Executive Officer.
RELOCATION OF CORPORATE HEADQUARTERS
The Company has also relocated its headquarters to 1065 East Hillsdale
Blvd., Suite 418, Foster City, CA 94404. Its new telephone number at that
location is (415) 524-1600, and its new telephone number for facsimile
transmissions is (415) 524-1616.
<PAGE>
ITEM 7: FINANCIAL STATEMENTS AND EXHIBITS.
(c) Exhibits.
The following exhibits are filed herewith:
20.01 Press Release
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.
Date: July 25, 1996
CELLEGY PHARMACEUTICALS, INC..
By: /s/ A. Richard Juelis
--------------------------
A. Richard Juelis
Chief Financial Officer
<PAGE>
INDEX TO EXHIBITS
Exhibit Sequentially
Number Description of Exhibit Numbered Page
------- ---------------------- -------------
20.01 Press Release 5
EXHIBIT 20.01
CELLEGY ANNOUNCES THE DEATHS OF TWO EXECUTIVES
NOVATO, Calif., July 11/PRNewswire/ -- Cellegy Pharmaceuticals, Inc.
(Nasdaq: CLGY; Warrants, CLGYW) regrets to announce that its President and Chief
Executive Officer, William E. Bliss, and its Vice President of Corporate
Development, Lionel D. Simon, Ph.D., were killed in an automobile accident while
traveling home together on Tuesday evening, July 9, 1996.
Carl R. Thornfeldt, M.D., Chairman of the Board and founder of Cellegy,
has assumed the position of acting CEO pending recruitment of a replacement for
Mr. Bliss.
Cellegy's Board of Directors met yesterday to establish a transition
committee responsible for continuity of the Company's business strategy,
business development and operations. Chaired by Dr. Thornfeldt, the committee
includes Richard Juelis, Vice President, Finance and Chief Financial Officer;
Dr. Michael Francoeur, Vice President, Research and Development; and Denis R.
Burger, Ph.D., a board member. Mr. Juelis will be responsible for Cellegy's
administrative and investor relations activities, while Dr. Francoeur will be
responsible for the Company's research and technical development activities.
Both men have senior management experience in the pharmaceutical industry.
Cellegy also established a committee whose primary responsibility will
be to recruit a new CEO. This committee will be chaired by Dr. Burger, who is an
executive officer at three other biomedical companies. Heidrich & Struggles, the
executive recruiting firm that originally recruited Mr. Bliss, will also assist
in the search. "We are deeply saddened by the loss of William Bliss and Lionel
Simon," said Dr. Thornfeldt. "On behalf of myself, the Board of Directors and
the employees of Cellegy, we offer our deepest sympathies to their families."
"Since joining Cellegy, Bill and Lionel had made outstanding
contributions that moved the Company to new height. These included building a
strong management team and board group and aggressively pursuing key corporate
relationships and licensing agreements. Thanks to these activities, we are
confident Cellegy will be able to meet its goals in research and business
development programs in the months and years to come."
Cellegy is a pharmaceutical company engaged in the development, through
corporate collaborations and marketing arrangements, of innovative drug delivery
products as well as consumer and prescription products for the skin.
-0-
/CONTACT: Richard Juelis, Chief Financial Officer of Cellegy
Pharmaceuticals, Inc., 415-382-6770, or Jimmy Caplan of Market Makers,
805-569-0076, or Rick Eisenberg of Eisenberg Communications, 212-496-6828/
(CLGY)
